關(guān)鍵詞： Merck 神經(jīng)系統(tǒng)科學(xué)項(xiàng)目 Cerecor
2013年4月22日訊 /生物谷BIOON/ --位于美國(guó)城市巴爾的摩的Cerecor生物技術(shù)公司已經(jīng)從Merck公司獲取了兩項(xiàng)關(guān)于神經(jīng)系統(tǒng)科學(xué)的研究項(xiàng)目,。這兩項(xiàng)項(xiàng)目分別是對(duì)MK-0657和catechol-O-methyltransferase (COMT)抑制劑兩種新型藥物的研究,。Cerecor稱獲得這兩種藥物的研發(fā)銷售權(quán)利有利于公司在神經(jīng)科學(xué)領(lǐng)域的深入研究。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
Cerecor, a Baltimore-based biotech focused on neuroscience, has picked up two CNS programs from the U.S. drug giant Merck ($MRK). The biotech outfit acquired exclusive global rights to MK-0657, an NR2B antagonist, as well as similar rights to catechol-O-methyltransferase (COMT) inhibitors from Merck. Merck initially studied MRK-0657 for Parkinson's disease, yet Cerecor says that the compound impacts a pathway involving depression and other disorders. The COMT inhibitors also offer the potential to treat multiple neuroscience targets.
(責(zé)任編輯：lili.zhao)
